The highly conserved cluster of high-mannose glycans on the HIV-1 envelope glycoprotein, gp120, has been highlighted as a target for neutralizing antibodies. 2G12, the first HIV-1 antiglycan neutralizing antibody described, binds with an unusual domainexchanged structure that creates a high-affinity multivalent binding surface. It is an interesting challenge for rational vaccine design to generate immunogens capable of eliciting domain-exchanged 2G12-like responses. We recently showed that di-mannose recognition by the variable domains of 2G12 is independent of domain exchange but that exchange is critical for virus neu- 
T he human immunodeficiency virus type 1 (HIV-1) envelope glycoprotein, gp120, is heavily glycosylated, with 50% of its mass comprising carbohydrate. A number of HIV-1 broadly neutralizing antibodies (bnAbs) have been isolated from HIV-infected individuals that bind to, or are dependent on, these Nlinked glycans (1) (2) (3) (4) (5) (6) (7) (8) (9) . Design of carbohydrate-based immunogens that "reelicit" these antibodies through vaccination is of considerable interest. Antibody 2G12 was the first bnAb shown to bind the high-mannose glycans on gp120 (5, 6, 10) . 2G12 binds to its high-mannose epitope through a unique domain-exchanged structure where the heavy chain variable domains cross over to create an extended multivalent binding surface consisting of two conventional primary binding sites in addition to a potential nonconventional binding site at the V H /V H = interface (1) . Through this unique structure, 2G12 is able to overcome the typically weak carbohydrate-protein interactions and bind its glycan epitope with nanomolar affinity. Unlike the recently identified bnAbs PGT128 and PG9, which contact two glycans and protein surfaces (3, 4) , 2G12 has been shown to bind glycans alone.
2G12 is an attractive template for vaccine design, as it has been shown to protect macaques against simian-human immunodeficiency virus (SHIV) challenge at low serum neutralizing titers (11, 12) . It is also a challenge for rational vaccine design to generate immunogens capable of eliciting domain-exchanged antibodies. There have been many attempts to elicit HIV broadly neutralizing carbohydrate-specific antibodies using both chemically and biochemically prepared multivalent and clustered displays of the 2G12 glycan antigens Man 4 (D1 arm) and Man 9 . These have included whole yeast cells (13) (14) (15) , bacteria (16) , oligodendrons (17) , and Q␤ particles (18, 19) . Although many of these immunogens have generated mannose-specific antibodies, thus far, none have generated a broadly neutralizing response against HIV.
We have recently shown that disruption of the stabilizing V H / V H = interface in wild-type 2G12 (2G12 WT) by reverting Ile at position H19 to Arg (as in the germ line) results in a fully nondomain-exchanged antibody (2G12 I19R) (20) . Crystallography showed that the primary binding site of this variant was identical to that of domain-exchanged 2G12 (2G12 WT) and that the molecular details of the recognition of Man␣1,2Man were very similar. The 2G12 I19R variant was able to bind to synthetically arrayed Man␣1,2Man epitopes and to the yeast pathogen Candida albicans. However, the antibody was unable to bind to recombinant gp120 or to neutralize HIV-1 pseudovirus, indicating that domain exchange is essential for HIV reactivity. We therefore concluded that the major shortcoming of the carbohydrate HIV immunogens tested thus far is their inability to elicit mannosespecific domain-exchanged antibodies or antibodies with a highenough affinity.
In a second study, we showed that a domain-exchanged antibody could be generated from a germ line version of the antibody with a reasonably small number of mutations (21) . For example, only 5 or 8 substitutions in germ line 2G12 (2G12 gl) were required to achieve 27% and 37% domain exchange, respectively (determined by size exclusion of the Fab fragment [1] ). These findings, in addition to our observation that a non-domain-exchanged 2G12 variant has an essentially unchanged antigen binding site, led us to propose an evolutionary pathway whereby Man␣1,2Man specificity arose in a conventional antibody and subsequent domain exchange enabled high-avidity recognition of the clustered high-mannose glycans on HIV-1. We therefore proposed an immunization strategy in which antimannose antibodies would first be elicited by immunization with an extended array of mannose, which would be followed by immunization with discrete clusters of oligomannose, as on gp120, to drive domain exchange of the mannose-specific antibodies.
Here, to further explore this hypothesis, we prepared three mouse B cell lines expressing domain-exchanged 2G12 WT, the non-domain-exchanged 2G12 I19R variant, and 2G12 gl as IgM B cell receptors (BCRs). We used changes in intracellular calcium levels to measure the ability of both HIV envelope glycoproteins and candidate glycoconjugate vaccines to activate these B cell lines and therefore determine the potential of carbohydrate immunogens to elicit Y-shaped or domain-exchanged antibodies in vivo. We show that several of these immunogens are able to activate both 2G12 WT and 2G12 I19R B cell lines, whereas the discrete cluster of oligomannose glycans, as on recombinant forms of the HIV trimer and oligodendrons, can selectively activate the domain-exchanged 2G12 WT cells. Discouragingly, none of the immunogens tested were able to activate the germ line 2G12 B cells. The engineered B cell lines were more sensitive than standard enzyme-linked immunosorbent assay (ELISA) binding assays and may aid in the design of immunization strategies and immunogens that might reelicit 2G12-like domain-exchanged antibodies in vivo.
MATERIALS AND METHODS
K46 mouse B cells were prepared as described previously by Ota et al. (22) . Briefly, for the heavy chain constructs, variable heavy chain coding sequences were appended with a mouse promoter and leader and cloned into the pSal (23) mouse genomic IgM expression vector. For light chain constructs, a mouse Vk leader sequence and a human kappa constant region were fused to the antibodies' variable light chain. Coding sequences were expressed under the control of the EF-1␣ promoter (NotI and BglII) in the pBudCE4.1 expression plasmid (Invitrogen, Carlsbad, CA).
The V(D)J sequences of 2G12 WT, 2G12 I19R, and 2G12 gl were previously described (10, 20, 21) . About 10 g of both heavy-and lightchain-linearized (SalI and NheI, respectively) expression vectors was added to 5 ϫ 10 6 K46 cells in 500 l Dulbecco's modified Eagle's medium (DMEM) and incubated in 4-mm cuvettes on ice for 5 min. Cells were electroporated with a Gene Pulser Xcell instrument (Bio-Rad, Hercules, CA) at 230 V, 960 F, and ϱ ⍀, resulting in a time constant of ϳ35 ms. Cells were placed on ice for 10 min and seeded into 10-cm dishes containing 10 ml complete medium (DMEM, 10% fetal calf serum [FCS] , 55 M ␤-mercaptoethanol, 2 mM L-glutamine, 100 g/ml streptomycin, 100 IU/ml penicillin, 100 M nonessential amino acids). Selection was started after 0 to 2 days with 1 mg/ml G418 (Gibco, Carlsbad, CA) for heavy chain transfection and/or 1 mg/ml zeocin (Invitrogen, Carlsbad, CA) for light chain transfection, respectively. Calcium flux. Cells were suspended at 4 million cells/ml in assay buffer and labeled with Fluo-4 NW dye (Life Technologies, Grand Island, NY) according to the manufacturer's recommendations. For activation experiments, 400 l of cells (at 2 ϫ 10 6 cells/ml) was stimulated. A baseline was recorded for 10 s before addition of the BCR ligand. Ca 2ϩ signals were recorded for 220 s on an LSR II flow cytometer (BD, San Jose, CA). Kinetic analysis was performed by using FlowJo (Tree Star, Ashland, OR). gp140 JR-FL trimer was expressed in HEK-293T cells.
Fluorescence-activated cell sorter (FACS) binding assays. Binding of biotinylated antigens or antibodies to K46 cells was measured on a BD Accuri C6 flow cytometer (BD, San Jose, CA) using either directly labeled antibodies (anti-mouse IgM and anti-human kappa; Jackson) or biotinylated antigens (biotin-JR-FL trimer or biotin-M1G1) and a streptavidinphycoerythrin (PE) secondary probe. FlowJo 7.6 (Tree Star, Ashland, OR) and Prism 5.0 for Mac (GraphPad, La Jolla, CA) were used for analysis.
ELISA binding assays. (i) Antigen coating.
Costar high-binding microtiter 96-well plates (type 3690; Corning Life Sciences, Lowell, MA) were coated with 250 ng of antigen overnight at 4°C. Plates were blocked, and serial dilutions of 2G12 WT and 2G12 I19R were incubated for 2 h. Unbound antibody was removed by washing with phosphate-buffered saline (PBS)-0.05% Tween 20. Binding was detected with goat anti-human Fc␥ AP conjugate (1:1,000; Jackson ImmunoResearch, West Grove, PA) and p-nitrophenol phosphate substrate (Sigma) at 405 nm.
(ii) Antibody coating. Plates were coated with a serial dilution of 2G12 WT, 2G12 I19R, and 2G12 gl. Q␤ glycoconjugates were added at a constant concentration of 5 g/ml. Binding was detected using Q␤ rabbit immune serum and goat anti-rabbit Fc␥ alkaline phosphatase (AP) conjugate (1:1,000; Jackson) and p-nitrophenol phosphate substrate at 405 nm.
RESULTS

Preparation of K46 B cell lines displaying 2G12 WT, 2G12 I19R, and 2G12 gl antibodies. Mouse B cells expressing IgM versions of 2G12 WT, 2G12 I19R
, and 2G12 gl antibodies were generated. The membrane-bound antibodies were expressed as chimeras of the human variable regions fused to the constant regions of mouse heavy chains and human light chains. The K46 mouse B cell line (24) was transfected by electroporation with separate vectors containing the heavy and light chain immunoglobulin genes. Clones were selected for stable and high-level expression by fluorescenceactivated cell sorting (FACS). Coexpression of the heavy and light chains was shown by staining with anti-human kappa and antimouse IgM heavy chain antibodies (Fig. 1A) . The functional integrities of the B cell receptors (BCRs) on these cell lines were determined by monitoring increases in intracellular Ca 2ϩ levels by FACS upon stimulation with a polyclonal anti-mouse IgM (Jackson) (Fig. 1C) . The anti-2G12 idiotypic antibody M1G1 was used to show that only the 2G12 WT cells displayed domain-exchanged receptors (Fig. 1B) (21, 25) .
Binding and activation of cell lines with recombinant HIV trimers. We have previously shown that recombinant HIV envelope trimers are able to induce calcium flux in several engineered B cell lines expressing HIV-neutralizing antibodies, including 2G12 WT cells (22) . To determine if HIV envelope proteins could activate the 2G12 I19R and 2G12 gl cells, we measured calcium flux upon the addition of a recombinant JR-FL trimer. Although the trimer was able to activate calcium flux of the 2G12 WT cells at concentrations as low as 2.8 nM, no response was observed for 2G12 I19R or 2G12 gl cells at concentrations of up to 138.9 nM (Fig. 2A) . Furthermore, no binding of the JR-FL trimer to 2G12 I19R or 2G12 gl cells was detected at 27.8 nM, similar to our previous observations for soluble IgG by ELISA (Fig. 2B) (20, 21) .
Arrangement of high-mannose glycans on synthetic glycoconjugate immunogens determines activation of 2G12 WT and 2G12 I19R cells. First, we were interested to determine whether multivalent displays of Man 4 and Man 9 antigens on icosahedral Q␤ bacteriophage particles could activate any of our 2G12 B cell lines (18, 19, 26) . We have previously shown that 2G12 WT can bind these immunogens with nanomolar affinity (20 to 50 nM). However, binding of 2G12 I19R was very weak and was detected only if the avidity of the antibody was enhanced either by precomplexing the antibody with an anti-human-Fc antibody before addition to the ELISA plate or by immobilizing the antibody directly on the plate at a high density (20) (Fig. 3D and E) . Both immunogens tested were able to activate the 2G12 I19R B cells weakly at 20 g/ml (Fig. 3A) , demonstrating the potential advantage of these B cell lines over conventional ELISA binding for immunogen screening. The activation of domain-exchanged 2G12 WT cells was more rapid and stronger in magnitude than for 2G12 I19R cells (Fig. 3A) and could be detected at concentrations as low as 0.2 g/ml. "Naked" Q␤ particles were unable to flux calcium (Fig.  3A) . Neither immunogen was able to activate the 2G12 gl cells at concentrations of 50 g/ml (data not shown), supporting previous studies that failed to detect binding of soluble 2G12 gl IgG to glycans (21) .
We previously investigated the potential of a nonself variant of the D1 arm displaying a methyl group at the C-6 position of the terminal mannose residue to elicit HIV-reactive antibodies (19) . Although this glycan had enhanced 2G12 antigenicity and there was a slightly higher immune response than with the self D1 arm, no HIV-neutralizing antibodies were elicited. Using Q␤-Man 4 (self D1 glycan) and Q␤-Man 4 B (nonself variant), we observed enhanced activation for 2G12 I19R B cells by the nonself sugar. However, the response was comparable for 2G12 WT B cells at the concentrations tested (Fig. 3A) . When the loading of Q␤-Man 4 B particles was increased from approximately 360 glycans (Q␤-Man 4 B-L) to 600 glycans (Q␤-Man 4 B-H) the magnitude of the B cell response for 2G12 I19R was greatly increased, presumably due to increased BCR crosslinking (Fig. 3B ) and increased antibody affinity (Fig. 3D) . Activation of 2G12 gl cells was still not observed.
Finally, oligodendrons displaying nine Man 9 glycans were conjugated to bovine serum albumin (BSA) (approximately 4 oligodendrons per BSA) (17) . These immunogens differ from the Q␤-based immunogens, as each dendron represents a discrete cluster of glycans rather than an extended array. Unlike the Q␤-based immunogens, these conjugates were unable to activate 2G12 I19R B cells at concentrations of up to 20 g/ml (Fig. 3C) . However, 2G12 WT B cells were activated at concentrations as low as 0.02 g/ml.
Yeast and bacterial pathogens activate 2G12 WT and 2G12 I19R B cells. We have previously shown that 2G12 WT IgG and 2G12 I19R IgG are able to bind to Candida albicans, a yeast strain with a polysaccharide coat consisting of a repeating Man␣1,6Man backbone and Man␣1,2Man-linked branches (20, 27) . Addition of approximately 1 ϫ 10 7 heat-killed Candida albicans cells induced calcium flux in both 2G12 WT and 2G12 I19R cells but not in 2G12 gl cells (Fig. 4A) . Saccharomyces cerevisiae, a yeast strain for which the Man␣1,2Man-linked branches are capped with an ␣1,3-linked mannose, was unable to induce calcium flux in these cells. The difference in the rate and magnitude of calcium flux correlates with the differences in binding affinities seen previously by flow cytometry (20) .
Clark and coworkers recently showed that the plant bacterium Rhizobium radiobacter Rv3 is able to inhibit the interaction between 2G12 and gp120 (16) . The lipooligosaccharide (LOS) contains a unique tetramannose motif in its carbohydrate backbone that is analogous to the D1 arm of Man 9 GlcNAc 2 . Addition of approximately 1 ϫ 10 7 heat-killed bacteria to the K46 B cell lines was able to activate both the 2G12 WT and 2G12 I19R B cell lines (Fig. 4B ).
DISCUSSION
We have previously shown that only 5 amino acid substitutions in the germ line of 2G12 WT are required to induce approximately 27% domain exchange antibody (21) . In addition, we have shown that a non-domain-exchanged variant of 2G12 that has an essentially unchanged binding site is unable to bind gp120 or neutralize HIV pseudovirus but can bind the yeast pathogen Candida albicans displaying an array of Man␣1,2Man epitopes (20) . Combined, these observations suggest that once a mannose-specific B cell has acquired, through somatic mutation, several of the residues important for facilitating and stabilizing domain exchange, this B cell will display a small proportion of domain-exchanged BCRs. These BCRs will have a higher avidity for highly clustered mannose antigens, leading to selection and activation of these B cells in preference to those displaying conventional Y-shaped BCRs.
We have shown that an initial mannose-specific antibody response might be driven through immunization with synthetic arrays of the 2G12 glycan antigens Man 4 and Man 9 on Q␤ bacteriophage particles (Fig. 3A and B) or the microbes Candida albicans and Rhizobium radiobacter Rv3 (Fig. 4A and  B) . Although binding of soluble 2G12 I19R IgG to Q␤ glycoconjugates was weak and was detectable only by enhancing antibody avidity (20) (Fig. 3D and E) , glycan-specific activation of 2G12 I19R cells by these immunogens was still noted. This observation highlights the low affinities required for B cell activation (28, 29) and demonstrates the possible advantage of using the 2G12 B cell lines over ELISA binding for carbohydrate immunogen screening. The magnitude and rate of activation of 2G12 I19R were enhanced by a nonself modification of the Man 4 antigen (Fig. 3A) and by increasing the valency of antigen coupling on Q␤ particles (Fig. 3B) , presumably due to increased binding avidities (Fig. 3D) . The magnitude and rate of B cell activation were higher for 2G12 WT than for 2G12 I19R cells. This might be a reflection of the level of BCRs on the different B cell lines but may also be due to differences in binding affinity (20) . The observation that these immunogens activate both 2G12 WT and 2G12 I19R B cell lines may be an indication of why they did not elicit a domain-exchanged antibody response when tested in vivo in rabbits (13-16, 18, 19) . Immunogens that could selectively activate B cells displaying domain-exchanged BCRs and therefore potentially drive domain exchange of the initial antimannose antibody response were shown to include synthetic clusters of Man 9 (i.e., oligodendrons) and recombinant HIV envelope glycoproteins (i.e., JR-FL trimer). The unusual domain exchange structure of 2G12 allows multivalent binding to the highly clustered glycans on both gp120 and Man 9 oligodendrons (1, 30). However, due to the low affinity of 2G12 I19R for its di-mannose epitope, a simultaneous interaction of both Fab arms is required to detect binding, and, presumably because the geometry of these high-mannose clusters does not accommodate both Fab arms of 2G12 I19R, no activation was seen (31) (32) (33) . Our observations that both yeast and bacterial pathogens displaying D1 arm motifs within their polysaccharide coats are able to activate 2G12 I19R cells and that JR-FL trimer activates only 2G12 WT cells support the hypothesis that 2G12 may have evolved from a Y-shaped mannose-specific antibody in an individual initially infected with either of these pathogens (20, 27, 34) . When this individual subsequently became infected with HIV-1, the highly clustered high-mannose glycans on gp120 were the driving force for domain exchange.
In this study, no immunogen tested could initiate calcium flux in the 2G12 gl K46 cell line, consistent with previous observations that 2G12 gl IgG was unable to bind gp120 or highmannose glycans on a glycan microarray (21) . Although some germ-line-reverted bnAbs weakly bind HIV envelope glycoproteins (35-37), JR-FL trimer did not activate calcium flux in 2G12 gl K46 B cells. This is not unexpected given that domain exchange of 2G12 is critical for binding the clustered highmannose glycans on gp120 (20) . However, the inability of multivalent arrays of oligomannose glycans to activate 2G12 gl B cells raises the questions, Which molecule(s) initially activated the 2G12 germ line BCR in this individual, and which immunogen(s) could be used in an immunization protocol to initiate an antimannose response? As glycans are typically T-cell-independent antigens, the recognition of glycans is thought to be more dependent on the primary germ line gene repertoire (38, 39) . For example, unmutated germ line antibodies (including the IGHV3-21 gene used by 2G12) have been shown to interact with the capsular polysaccharide of Streptococcus pneumoniae (40) . These antibodies have low specificity and bind to several polysaccharide serotypes as well as blood group antigens. It therefore may be possible that 2G12 gl was activated by another bacterial pathogen displaying an unrelated polysaccharide or polymer. However, it is also possible that there is a weak interaction with the 2G12 gl BCRs by the types of antigens that we tested but that the threshold for activation was not reached.
In summary, if an appropriate immunogen that can activate 2G12 gl can be identified, our results suggest that an immunization protocol to elicit domain exchange antibodies will require an immunogen prime to elicit mannose-specific conventional Y-shaped antibodies followed by a boost with a highly clustered display of oligomannose glycans that selectively activates only those B cells displaying a fraction of domain-exchanged B cell receptors due to increased avidity. Additional somatic mutation would select B cells with an increasing proportion of domainexchanged BCRs. The engineered 2G12 K46 B cell lines are useful tools to screen potential immunogens for both the prime and boost components of this proposed strategy to elicit domain-exchanged antibodies.
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